 |
|
|
|
|
|
|
|
|
Talecris-Sponsored Scientific Symposium Examines Advances in Use of Intravenous Immune Globulin for Neurological Disorders
Special Session Held at European Federation of Neurological Societies Congress
RESEARCH TRIANGLE PARK, N.C. and BRUSSELS, BELGIUM (August 27, 2007) – A scientific symposium which featured the latest information on potential therapeutic applications of intravenous immune globulin (IVIG) in neurological disorders was presented yesterday at the 11th Congress of the European Federation of Neurological Societies in Brussels, Belgium. The program, entitled “Advances in the Use of IVIG in Neurological Disorders,” was sponsored by Talecris Biotherapeutics, Inc. (http://www.talecris.com). The program featured presentations and discussions of the growing evidence supporting use of IVIG to treat a variety of neurological disorders including autoimmune neuropathies and other autoimmune neurological disorders.
The program, chaired by Dr. Hans-Peter Hartung, Department of Neurology, Heinrich-Heine University, Düsseldorf, Germany, included experts in neurology and IVIG therapy who presented the latest scientific and clinical data. Presentations focused on the mechanisms of action of IVIG in neurological disorders, evidence supporting the use of IVIG for autoimmune neuropathies including chronic inflammatory demyelinating polyneuropathy (CIDP), and the current status and future prospects of IVIG in other autoimmune disorders of the neurological system.
“This program provided an excellent overview of what scientists and medical professionals have learned about immune-based pathophysiological mechanisms for neurological disorders, and how IVIG might provide new approaches to treatment,” said Dr. Hartung. “We thank Talecris for their support of this important program and their commitment to advancing scientific knowledge surrounding potential neurological uses of IVIG.”
Contact:
Lacy McMahon, Talecris Biotherapeutics
Tel.: 919.316.6316, Fax: 919.316.6673
E-mail: lacy.mcmahon@talecris.com
About Talecris Biotherapeutics: Inspiration. Dedication. Innovation.
Talecris Biotherapeutics is a global biotherapeutic and biotechnology company that discovers, develops and produces critical care treatments for people with life-threatening disorders in a variety of therapeutic areas including immunology, pulmonology, and hemostasis. Talecris is proudly building upon a 60-year legacy of innovation and a commitment to improving the lives of people who rely on its therapeutic products. With an emphasis on scientific inquiry and technological excellence, Talecris is expanding its current portfolio of products, programs, and services through its own world-class product development organization as well as through strategic initiatives that leverage its strengths with those of its partners.
Talecris, with revenues of approximately $1.2 billion in 2007, is headquartered in biotech hub Research Triangle Park, N.C., and employs more than 4,000 talented people worldwide.
To learn more about Talecris and how our employees are making a difference in the lives of patients and the healthcare community, visit www.talecris.com.
|
|
|
|
|
|
|
|
